Healthy volunteers help test new drug NAV-240 for first time in humans
Knowledge-focused
Completed
This early-stage study tested the safety of a new drug, NAV-240, in 24 healthy adults. Participants received either the drug or a placebo to see what side effects might occur. The goal was to gather initial safety information, not to treat any disease.
Phase: PHASE1 • Sponsor: Navigator Medicines, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC